GTAEXS-617

N/A

Report date: 2026/04/07 20:00:20
NMEFirst In Class

Base Information

Drug NameGTAEXS-617
Drug Alias NameGTAEXS-617'617EXS-617REC-617
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 7 inhibitors
TargetsCyclin-dependent kinase 7
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Apeiron Biotechnology Co LtdRecursion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRecursion Pharmaceuticals IncShanghai Apeiron Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A